RTP Mobile Logo
Hematologic Oncology Update, Issue 3, 2012
Released January 2013

Featuring interviews with Drs Michael E Williams, P Leif Bergsagel, Jorge E Cortes and Lauren C Pinter-Brown. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.


    LEARNING OBJECTIVES
    • Integrate recent clinical research findings with proteasome inhibitors and immunomodulatory agents into the development of individualized induction and maintenance treatment strategies for patients with multiple myeloma.
    • Compare and contrast the benefits and risks of approved first- and second-generation tyrosine kinase inhibitors and protein translation inhibitors as therapeutic options for patients with chronic myeloid leukemia.
    • Develop an understanding of emerging efficacy and side-effect data with JAK2 inhibitors in myelofibrosis in order to inform patients regarding protocol and nonprotocol treatment options.
    • Counsel patients with follicular and mantle-cell lymphoma about recent advances in induction and maintenance systemic treatment, and integrate these advances into current treatment algorithms as appropriate.
    • Describe the biologic rationale for and emerging roles of novel and approved antibody-drug conjugates — alone and in combination with chemotherapy — in the treatment of Hodgkin lymphoma, acute lymphoblastic leukemia and other CD30- or CD22-positive hematologic disorders.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr WilliamsAdvisory Committee: Celgene Corporation, Genentech BioOncology, Onyx Pharmaceuticals Inc; Consulting Agreements: Celgene Corporation, Genentech BioOncology; Paid Research: Allos Therapeutics, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Cephalon Inc, Genentech BioOncology, Gilead Sciences Inc, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation. Dr BergsagelConsulting Agreement: Onyx Pharmaceuticals Inc. Dr CortesAdvisory Committee: Boehringer Ingelheim Pharmaceuticals Inc; Consulting Agreements: Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Pfizer Inc; Paid Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi. Dr Pinter-BrownConsulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS
    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This activity is supported by educational grants from Allos Therapeutics, Genentech BioOncology/Biogen Idec, Incyte Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    Hardware/Software Requirements:

    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2013
    Expiration date: January 2014

Acknowledge and close

Listen to audio:
Hematologic Oncology Update, Issue 3, 2012
Released January 2013

Featuring interviews with Drs Michael E Williams, P Leif Bergsagel, Jorge E Cortes and Lauren C Pinter-Brown. (Text and Audio Content)

Read print: